학술논문

Sex differences in acute stroke metrics and outcome dependent on COVID status.
Document Type
Article
Source
European Journal of Neurology. May2024, Vol. 31 Issue 5, p1-7. 7p.
Subject
*STROKE
*THROMBOLYTIC therapy
*ISCHEMIC stroke
*COVID-19
*COVID-19 pandemic
*ENDOVASCULAR surgery
Language
ISSN
1351-5101
Abstract
Background and purpose: Biological sex is known to have an impact on quality metrics of acute stroke. We aimed to determine whether COVID positivity accentuates this effect and constitutes worse outcome. Methods: The present analysis was based on the Global COVID‐19 Stroke Registry, a retrospective, international, cohort study of consecutive ischemic stroke patients receiving intravenous thrombolysis and/or endovascular thrombectomy between 1 March 2020 and 30 June 2021. We investigated differences between the sexes in patient characteristics, acute stroke metrics as well as post‐stroke outcome in COVID‐positive and COVID‐negative stroke patients undergoing acute revascularization procedures. Results: A total of 15,128 patients from 106 centers were recorded in the Global COVID‐19 Stroke Registry, 853 (5.6%) of whom were COVID‐positive. Overall, COVID‐positive individuals were treated significantly slower according to every acute stroke metric compared to COVID‐negative patients. We were able to show that key quality indicators in acute stroke treatment were unfavorable for COVID‐negative women compared to men (last‐seen‐well‐to‐door time + 11 min in women). Furthermore, COVID‐negative women had worse 3‐month outcomes (3‐month modified Rankin Scale score [interquartile range] 3.0 [4.0] vs. 2.0 [3.0]; p < 0.01), even after adjusting for confounders. In COVID‐positive individuals no such difference between the sexes, either in acute management metrics or in 3‐month outcome, was seen. Conclusion: Known sex‐related differences in acute stroke management exist and extend to times of crisis. Nevertheless, if patients were COVID‐19‐positive at stroke onset, women and men were treated the same, which could be attributed to structured treatment pathways. [ABSTRACT FROM AUTHOR]